Search Results

You searched for : LatestPfizerNews  

FIRST PARTICIPANT DOSED IN PFIZER’S PIVOTAL PHASE 3 TALAPRO-3 COMBINATION STUDY OF TALAZOPARIB AND ENZALUTAMIDE

...
Jun 23

DATA PUBLISHED IN NEW ENGLAND JOURNAL OF MEDICINE SHOWS PFIZER’S TOFACITINIB MEETS PRIMARY ENDPOINT IN BRAZILIAN STUDY IN PATIENTS HOSPITALIZED WITH COVID-19 PNEUMONIA

It is important to note that tofacitinib has not been approved or authorized for use by any regulatory authority worldwide for the treatment of COVID-...
Jun 17

PFIZER AND BIONTECH TO PROVIDE 500 MILLION COVID-19 VACCINE TO U.S. GOVERNMENT FOR DONATION TO POOREST NATIONS

These doses are part of Pfizer and BioNTech’s previously announced pledge to provide two billion doses of the COVID-19 vaccine to low- and ...
Jun 10

Pfizer and Biontech publish results of study showing COVID-19 vaccine elicits antibodies that neutralize Pseudovirus bearing the SARS-COV-2 U.K

While the pseudovirus system used is a surrogate for authentic SARS-CoV-2, previous studies have shown excellent concordance between pseudotype neutralization and SARS-CoV-...
Jan 21

Pfizer invests $120 million in biotechnology innovation through the Pfizer breakthrough growth initiative

Through PBGI, Pfizer is investing up to $500 million in biotechnology companies, providing funding and access to Pfizer’s scientific expertise to help ensure the ...
Jan 13

Pfizer doses first participants in phase 3 study for Duchenne Muscular Dystrophy investigational Gene Therapy

CIFFREO is a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study....
Jan 07

US FDA accepts regulatory submission from PFIZER and OPKO for review of somatrogon

Pfizer inc. and OPKO Health Inc. announced today that the USFDA has accepted for filing the initial Biologics License Application for somatrogon, a long-acting ...
Jan 05

PFIZER AND BIONTECH TO SUPPLY THE U.S. WITH 100 MILLION ADDITIONAL DOSES OF COVID-19 VACCINE

...
Dec 24

U.S. FDA ACCEPTS FOR PRIORITY REVIEW THE BIOLOGICS LICENSE APPLICATION FOR PFIZER’S INVESTIGATIONAL 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE

The FDA’s acceptance of our application for 20vPnC is yet another significant milestone in Pfizer’s continuing efforts to help protect adults against pneumococcal ...
Dec 09

PFIZER REPORTS POSITIVE CLINICAL DATA FOR BCMA-CD3 BISPECIFIC ANTIBODY IN MULTIPLE MYELOMA

...
Dec 08

PFIZER AND SANGAMO ANNOUNCE UPDATED PHASE 1/2 RESULTS FOR HEMOPHILIA A GENE THERAPY

We continue to be encouraged by the findings from this Phase 1/2 study, which now include durable factor VIII expression through one year of ...
Dec 07

PFIZER AND BIONTECH ACHIEVE FIRST AUTHORIZATION IN THE WORLD FOR A VACCINE TO COMBAT COVID-19

...
Dec 02

PFIZER DOSES FIRST PARTICIPANT IN PHASE 3 STUDY EVALUATING ANTI-TFPI INVESTIGATIONAL THERAPY

An anti-tissue factor pathway inhibitor being evaluated for the treatment of people with severe hemophilia A or B, with or without inhibitors....
Nov 23

RESULTS FROM PHASE 3 CROWN TRIAL OF PFIZER’S LORBRENA IN PREVIOUSLY UNTREATED ALK-POSITIVE LUNG CANCER PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE

...
Nov 19

PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19 ACHIEVED SUCCESS IN FIRST INTERIM ANALYSIS FROM PHASE 3 STUDY

...
Nov 09

FDA GRANTS PRIORITY REVIEW AND EMA ACCEPTS REGULATORY SUBMISSION FOR PFIZER’S ABROCITINIB FOR PATIENTS WITH ATOPIC DERMATITIS

...
Oct 27

PENELOPE-B TRIAL OF IBRANCE (PALBOCICLIB) IN EARLY BREAST CANCER DID NOT MEET PRIMARY ENDPOINT

We are proud of the transformative impact IBRANCE has had on the treatment of HR+, HER2- metastatic breast cancer...
Oct 09

Pfizer reports weekly Somatrogon is more effective in human growth deficiency

Clinical Study proves weekly administration of Somatrogon more effective in treating human growth deficiency disease...
Oct 09

PENELOPE-B TRIAL OF IBRANCE (PALBOCICLIB) IN EARLY BREAST CANCER DID NOT MEET PRIMARY ENDPOINT

We are proud of the transformative impact IBRANCE has had on the treatment of HR+, HER2- metastatic breast cancer...
Oct 09

PFIZER AND SANGAMO DOSE FIRST PARTICIPANT IN PHASE 3 STUDY EVALUATING HEMOPHILIA

The initiation of the pivotal Phase 3 dosing study of giroctocogene fitelparvovec is a significant achievement for Pfizer as we continue our longstanding commitment to ...
Oct 07

BIONTECH AND PFIZER INITIATE ROLLING SUBMISSION TO EUROPEAN MEDICINES AGENCY FOR SARS-COV-2 VACCINE

Pfizer Inc. today announced the initiation of a rolling submission to the EMA for SARS-Cov-2 vaccine...
Oct 06

PFIZER RECEIVES FDA FAST TRACK DESIGNATION FOR DUCHENNE MUSCULAR DYSTROPHY

Pfizer Inc. today announced that its investigational gene therapy candidate being developed to treat Duchenne muscular dystrophy ...
Oct 01

U.S. FDA APPROVES PFIZER’S XELJANZ FOR THE TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS

Pfizer Inc. announced XELJANZ (tofacitinib) for the treatment of children 2 years and older with active polyarticular course juvenile idiopathic arthritis...
Sep 28

FDA ACCEPTS SUPPLEMENTAL NEW DRUG APPLICATION FOR PFIZER’S XALKORI

Pfizer Inc. today announced that the U.S. FDA has accepted and granted priority review to the Company’s supplemental New Drug Application for XALKORI ...
Sep 23

Pfizer Inc & BioNTech chooses mRNA-based vaccine candidate for trial

Pfizer and BioNTech choose lead mRNA vaccine candidate against COVID-19 and Pivotal Phase Global Study ...
Aug 01

25 Matching result(s) found!

-Advertisements-




Trending Now

Surviving Against the Odds: Steven Spinale's Journey After an Ingrown Hair Turns DeadlyMarch 29, 2024
10 reasons why media research and Planning are essential in Healthcare marketingMarch 29, 2024
The Surprising Link Between Sleep and Age Perception: What You Need to KnowMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 StudyMarch 29, 2024
Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024